Latest Administration News

Audeara Limited has achieved a key regulatory milestone with NMPA certification in China, paving the way for commercial launch of its hearing personalisation technology through a leading e-commerce brand. This approval supports the company’s strategy to generate scalable licensing revenue in a rapidly growing market.

Havilah Resources has secured a binding term sheet with Sandfire Resources for a potential $210 million earn-in at Kalkaroo, while reporting high-grade uranium results and raising $2 million in a share placement.

InhaleRx Limited has introduced SRX-25, an oral fixed-dose combination therapy targeting Treatment-Resistant Depression, aiming to improve patient access and adherence. The company also secured $1 million in capital to advance clinical development and plans a strategic rebrand.

Keybridge Capital Limited is navigating a complex recovery with new board leadership, partial loan repayments, and favorable court rulings against former executives. The company is steadily addressing legacy financial and legal challenges.

AKORA Resources has taken a pivotal step by submitting its application to convert the Bekisopa Iron Ore Project’s exploration licence into a mining licence, leveraging recent political reforms in Madagascar to unlock development and investment opportunities.

Straker Limited has significantly narrowed its interim loss despite a 15% revenue decline, driven by cost efficiencies and the absence of prior non-cash charges. The company also renewed a strategic $28 million partnership with IBM, reinforcing its AI language technology ambitions.

Riedel Resources Limited has announced a $1.78 million entitlement offer at a 26.5% discount to fund its Kingman Gold Project and corporate needs. Eligible shareholders in Australia and New Zealand can participate in this non-renounceable offer.

Jameson Resources Limited has updated its Employee Share Option Plan, approved at the 2025 AGM, aiming to better incentivize and retain key personnel while aligning employee interests with shareholders.

Metcash Limited has responded to an ASX query regarding the late filing of a director’s interest notice, attributing the delay to an administrative oversight and outlining plans to enhance compliance processes.

Mesoblast has achieved a landmark FDA approval for RYONCIL, the first allogeneic mesenchymal stromal cell therapy, driving strong commercial momentum and advancing a robust pipeline targeting inflammatory diseases.

Clarity Pharmaceuticals has raised $203 million to accelerate its copper-64 and copper-67 radiopharmaceutical pipeline, targeting prostate and neuroendocrine cancers with multiple FDA Fast Track trials underway.

Acrux Ltd reported a remarkable surge in licensing revenue from its topical generics portfolio alongside a strategic pivot towards innovative drug delivery R&D at its 2025 Annual General Meeting.